| Mandy Lea Sorlie, MD | |
|
904 5th Ave Ne, Jamestown, ND 58401-3437 | |
| (701) 253-4020 | |
| Not Available |
| Full Name | Mandy Lea Sorlie |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 17 Years |
| Location | 904 5th Ave Ne, Jamestown, North Dakota |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1649478090 | NPI | - | NPPES |
| 11013734A | Other | IN | MEDICAL RESIDENCY PERMIT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208D00000X | General Practice | 11013734A (Indiana) | Secondary |
| 207Q00000X | Family Medicine | 11582 (North Dakota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Jamestown Regional Medical Center | Jamestown, ND | Hospital |
| Sanford Medical Center Fargo | Fargo, ND | Hospital |
| Ave Maria Village | Jamestown, ND | Nursing home |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Sanford Medical Center Fargo | 8426967803 | 1094 |
News Archive
Scientists have shown that the retina has more light sensitivity and babies in the womb can see more than previously thought.
The 362,000-member National Taxpayers Union (NTU) today condemned the Senate Finance Committee's 14-9 vote to support the health care bill drafted by Senator Max Baucus (D-MT), pointing to hundreds of billions of dollars in damaging tax increases. This so-called "moderate" health care reform bill would grow the already bloated federal budget while saddling middle class families with billions in new taxes.
In a ground breaking study in the UK researchers have identified a previously unknown mechanism that allows the immune system to fight viruses even after they have infected cells. Until now it was believed that antibodies can act only before the virus enters the cells. The team now has found that antibodies that attached themselves to a virus were able to follow it into cells and help to destroy the virus before it started to reproduce. This could open up new avenues of therapy.
Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, announced today that it reached an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the Phase 3 clinical study named VISTA-16 (Vascular Inflammation Suppression to Treat Acute Coronary Syndrome - 16 Weeks) for its lead product candidate, A-002, an oral sPLA2 inhibitor, in combination with HMG-CoA reductase inhibitor, or statin, therapy for short-term (16-week) treatment of patients experiencing an acute coronary syndrome.
› Verified 9 days ago
| Entity Name | Sanford Clinic North |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942241351 PECOS PAC ID: 4284546151 Enrollment ID: O20031112000221 |
News Archive
Scientists have shown that the retina has more light sensitivity and babies in the womb can see more than previously thought.
The 362,000-member National Taxpayers Union (NTU) today condemned the Senate Finance Committee's 14-9 vote to support the health care bill drafted by Senator Max Baucus (D-MT), pointing to hundreds of billions of dollars in damaging tax increases. This so-called "moderate" health care reform bill would grow the already bloated federal budget while saddling middle class families with billions in new taxes.
In a ground breaking study in the UK researchers have identified a previously unknown mechanism that allows the immune system to fight viruses even after they have infected cells. Until now it was believed that antibodies can act only before the virus enters the cells. The team now has found that antibodies that attached themselves to a virus were able to follow it into cells and help to destroy the virus before it started to reproduce. This could open up new avenues of therapy.
Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, announced today that it reached an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the Phase 3 clinical study named VISTA-16 (Vascular Inflammation Suppression to Treat Acute Coronary Syndrome - 16 Weeks) for its lead product candidate, A-002, an oral sPLA2 inhibitor, in combination with HMG-CoA reductase inhibitor, or statin, therapy for short-term (16-week) treatment of patients experiencing an acute coronary syndrome.
› Verified 9 days ago
| Entity Name | Sanford Medical Center Fargo |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184917924 PECOS PAC ID: 8426967803 Enrollment ID: O20110331000495 |
News Archive
Scientists have shown that the retina has more light sensitivity and babies in the womb can see more than previously thought.
The 362,000-member National Taxpayers Union (NTU) today condemned the Senate Finance Committee's 14-9 vote to support the health care bill drafted by Senator Max Baucus (D-MT), pointing to hundreds of billions of dollars in damaging tax increases. This so-called "moderate" health care reform bill would grow the already bloated federal budget while saddling middle class families with billions in new taxes.
In a ground breaking study in the UK researchers have identified a previously unknown mechanism that allows the immune system to fight viruses even after they have infected cells. Until now it was believed that antibodies can act only before the virus enters the cells. The team now has found that antibodies that attached themselves to a virus were able to follow it into cells and help to destroy the virus before it started to reproduce. This could open up new avenues of therapy.
Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, announced today that it reached an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the Phase 3 clinical study named VISTA-16 (Vascular Inflammation Suppression to Treat Acute Coronary Syndrome - 16 Weeks) for its lead product candidate, A-002, an oral sPLA2 inhibitor, in combination with HMG-CoA reductase inhibitor, or statin, therapy for short-term (16-week) treatment of patients experiencing an acute coronary syndrome.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mandy Lea Sorlie, MD 904 5th Ave Ne, Jamestown, ND 58401-3437 Ph: (701) 253-4020 | Mandy Lea Sorlie, MD 904 5th Ave Ne, Jamestown, ND 58401-3437 Ph: (701) 253-4020 |
News Archive
Scientists have shown that the retina has more light sensitivity and babies in the womb can see more than previously thought.
The 362,000-member National Taxpayers Union (NTU) today condemned the Senate Finance Committee's 14-9 vote to support the health care bill drafted by Senator Max Baucus (D-MT), pointing to hundreds of billions of dollars in damaging tax increases. This so-called "moderate" health care reform bill would grow the already bloated federal budget while saddling middle class families with billions in new taxes.
In a ground breaking study in the UK researchers have identified a previously unknown mechanism that allows the immune system to fight viruses even after they have infected cells. Until now it was believed that antibodies can act only before the virus enters the cells. The team now has found that antibodies that attached themselves to a virus were able to follow it into cells and help to destroy the virus before it started to reproduce. This could open up new avenues of therapy.
Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, announced today that it reached an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the Phase 3 clinical study named VISTA-16 (Vascular Inflammation Suppression to Treat Acute Coronary Syndrome - 16 Weeks) for its lead product candidate, A-002, an oral sPLA2 inhibitor, in combination with HMG-CoA reductase inhibitor, or statin, therapy for short-term (16-week) treatment of patients experiencing an acute coronary syndrome.
› Verified 9 days ago
Dale J Ernster, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 401 3rd St Se, Jamestown, ND 58401 Phone: 701-253-5300 Fax: 701-253-5402 | |
Christopher Irmen, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 300 2nd Ave Ne, Jamestown, ND 58401 Phone: 701-253-4020 | |
David M Muhs, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 904 5th Ave Ne, Jamestown, ND 58401 Phone: 701-253-4020 Fax: 701-253-4040 | |
Sarah L Schatz, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 904 5th Ave Ne, Jamestown, ND 58401 Phone: 701-253-4000 | |
Dr. Kilby P Osborn Iv, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2430 20th St Sw, Jamestown, ND 58401 Phone: 701-253-5300 | |
Justin Jackson Rosenau, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 904 5th Ave Ne, Jamestown, ND 58401 Phone: 701-253-4000 | |
Callie Krause, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2605 Circle Dr, Jamestown, ND 58401 Phone: 701-253-3650 |